At the press conference of the new product of the universal translation of biological PolyseqX2 high-throughput nanopore sequencer, Liu Li, director of the Institute of Biophysics, Chinese Academy of Sciences, pointed out that sequencing technology, as the core pillar of modern life science, is the key support for disease prevention and control, precision medicine and frontier exploration of life science. From the launch of the first system to today's flagship new product release, every breakthrough of Polyseq Biotechnology not only continues to enhance China's international competitiveness in the sequencing field, but also strengthens the domestic technological barrier to safeguard national life and health and biological information security.

We are deeply proud of the achievements of the Polyseq Biotechnology team and will continue to fully support their innovative exploration and technological research and development in nanopore sequencing technology. We look forward to the team's continuous breakthroughs in DNA sequencing, RNA direct sequencing, epigenetic testing, and protein sequencing, developing more internationally competitive products and creating greater economic and social value! ”Liu Li stated.

Researcher Zhao Fangqing from the Institute of Zoology, Chinese Academy of Sciences, combined with his team's research practice in the field of tumor gene detection and pathogen detection, pointed out that the flexibility and controllability of nanopore sequencing technology has opened up a broader application exploration space for full spectrum transcript capture, targeted enrichment, unbiased quantification and other directions.

In the practical field with technological innovation as the core driving force, the value of technology ultimately needs to be anchored on the fundamental landing point of "solving practical problems".

Deng Kai, director of the Department of Genetic Medicine at Hebei Reproductive and Obstetrics Hospital, pointed out from a clinical application perspective that nanopore sequencing has important application value in the field of assisted reproduction. With its high-throughput characteristics, this technology can help achieve 24-hour fresh embryo transfer, which can not only reduce diagnosis and treatment costs for patients, but also significantly improve service quality. 

I am very much looking forward to the release of PolyseqX2 and believe that this product will become an important tool in the assisted reproductive industry! ”Deng Kai stated.

Polyseq Biotechnology is positioned as an upstream service provider in the industry, always with open cooperation as its core. We work together with partners to develop, expand, and create complete application solutions based on our sequencing platform. This direction has always been a strategic focus of Polyseq Biotechnology. Relying on this strategy, Polyseq Biotechnology has achieved rapid commercialization breakthroughs in the past year. Representatives from Bena Medical and Dafei Biotechnology were also invited to attend the press conference and share their cooperation experience. 

In the early application practice of the Polyseq platform, the various parameters and actual performance of the universal biological nanopore sequencing are comparable to similar products, and it has significant advantages in real-time, cost control, operational convenience, and iterative response speed. It not only has good adaptability in microbial detection related applications, but also has outstanding potential for application expansion. We are looking forward to the launch of this high-throughput platform. ”Yu Kaimin, Deputy General Manager of Beina Medical, stated.

Yao Yuan, Chairman of Dafei Biotechnology, pointed out that Polyseq Biotechnology has achieved a dual breakthrough of high throughput and high accuracy in a short period of time. Its chip quality is particularly excellent, and it can still be stably reused after multiple cleaning cycles. Some indicators have surpassed ONT. In terms of performance parameters, operational stability, cost control, and service response, Polyseq Biotechnology has demonstrated significant advantages and is a high-quality domestic alternative. We look forward to the latest release of high-throughput products continuing to bring more breakthroughs.

Dr. Wang Daqian, CEO of Polyseq Biotechnology, gave a detailed introduction to the core technological breakthrough of PolyseqX2 at the press conference.

The two PolyseqXCell sequencing chips paired with PolyseqX2, with a new ASIC chip design and sequencing chemistry system as the core, have achieved multiple technological breakthroughs:

In terms of detection capability, PolyseqXCell achieves PG level ultra-low initial detection with revolutionary substrate enrichment technology: while maintaining stable flux, the sample loading is only 1/30 of the C1.0 system, achieving a qualitative leap in detection sensitivity.

By relying on decoding technology upgrades, nucleic acid epigenetic modification information can be synchronously obtained with only a single sequencing, and the library has no chemical damage and long read length accurately covers complex areas, successfully achieving direct detection of DNA 5mC methylation modification.

In terms of stability, PolyseqX2 also performs excellently: integrating multiple noise reduction technologies significantly reduces detection noise and improves acquisition accuracy; By using a built-in analog-to-digital converter to achieve full digital signal output, the overall anti-interference ability is greatly enhanced, and the stability is further improved.

These technological breakthroughs have made PolyseqX2 a core tool for life science and medical research, which will strongly support the application and expansion of genomics, full-length transcriptomics, targeted amplification detection and other technologies. It is more suitable for expanding the application of sequencing technologies such as T2T genome and single-cell full-length transcriptomics in various research fields, and will become the cornerstone for promoting continuous breakthroughs in scientific research and clinical research.

A real-time sequencing demonstration of PolyseqX2 was conducted simultaneously at the press conference. From the real-time monitoring interface of the sequencing control software, it can be seen that the median Q value monitoring has exceeded 23.

In the field of cost control, Polyseq Biotechnology continues to deepen its cultivation. At the press conference, a practical case of extreme cleaning and reuse of cooperative customers' chips was specially showcased: the chips can still be used after 18 times of cleaning, highlighting that the chips can fully assist partners in minimizing application costs in terms of performance.

Regarding the Future: Inclusive Technology and Ecological Co construction

 

Dr. Wang Daqian stated in his blueprint for the future that the goal of Polyseq Biotechnology is to work with partners to connect the entire application chain, continue to deepen the cultivation of nanopore sequencing technology, and work together with global partners to usher in a new era of "precision, inclusiveness, and efficiency" in gene sequencing.

To this end, Polyseq Biotechnology will launch a low-cost chip with 1000 nanopores in the future, which will achieve full scene compatibility of low flux and high flux on the PolyseqX2 platform, providing maximum operational flexibility for partners, comprehensively assisting them in optimizing cost control, and empowering the industry to develop efficiently, healthily, and sustainably.

At last, Huang Yihua, the founder of Polyseq Biotechnology, thanked the guests, especially the trust and support of the Ministry of Science and Technology, the Chinese Academy of Sciences, the Institute of Biophysics, the Bioisland Laboratory, the Guangzhou National Laboratory and other institutions, as well as the attention and assistance of experts, scholars, investment institutions and partners attending the meeting. He emphasized that the success of PolyseqX2 stems from the team's more than 1300 day and night research and development efforts. In the future, we will continue to be driven by independent innovation, uphold the goal of "fast, accurate, portable, high-throughput, and low-cost", and provide high-quality sequencing solutions.

This press conference is not only a concentrated display of Polyseq Biotechnology's strength, but also marks the official entry of domestic nanopore sequencers into the international top tier. With the launch of PolyseqX2, China's independent and controllable capabilities in the field of gene sequencing equipment will be further enhanced, providing solid support for national strategies such as precision medicine and biosafety.

The breakthrough of gene sequencing technology has never been a solitary journey, but a collective leap forward in the entire industry chain. Polyseq Biotechnology is well aware that every step from technological innovation in the laboratory to universal clinical applications, from the improvement of industrial ecology to the advancement of life and health undertakings, cannot be separated from the side by side of partners.

In the future, we look forward to deepening collaboration with more research institutions, clinical units, and industry partners, starting from the technological breakthrough of PolyseqX2, to jointly connect the entire industry chain of "technology research and development application transformation clinical landing", and promote the acceleration of nanopore sequencing technology from "usable" to "user-friendly" and "universal".